Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biocure Technology Inc C.CURE

Alternate Symbol(s):  BICTF

Healthcare Biotechnology
Biocure Technology Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company is comprised of scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. In addition, the Company is developing Biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.


CSE:CURE - Post by User

Biocure Technology Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(73)
•••
Post by rocman01on Oct 16, 2018 12:54pm
153 Views
Post# 28811196

Great News under radar

Great News under radarhttps://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCURE-2670717&symbol=CURE&region=C

The trial results demonstrated a complete remission of the cancerous cells within 7 and 28 days from the injection of reengineered CAR-T cells into a mouse. The study further showed encouraging results as no toxicity symptoms have risen from the high-volume injection. Company believes these to be strong indicators for the next phase clinical trials.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities